星期六(002291.SZ):生產中心總經理趙洪武辭職
格隆匯12月19日丨星期六(002291.SZ)公佈,公司董事會近日收到公司生產中心總經理趙洪武的辭職報告。趙洪武因公司戰略轉型和業務架構調整原因,提出辭去公司生產中心總經理職務和佛山星期六科技研發有限公司(“研發公司”)法人代表和執行董事職務。辭職後,趙洪武先生將不在公司擔任任何職務。
根據《公司法》及《公司章程》的相關規定,趙洪武辭去生產中心總經理的職務自送達董事會時起生效;待研發公司的股權轉讓交易完成並辦理工商變更後,趙洪武將不再擔任研發公司法人代表、執行董事。公司董事會對趙洪武對公司所做的貢獻表示衷心感謝!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.